Do Multidisciplinary Meetings Follow Guideline-Based Care?

被引:57
作者
Vinod, Shalini K.
Sidhom, Mark A.
Delaney, Geoff P.
机构
[1] Liverpool Hosp, Collaborat Canc Outcomes Res & Evaluat CCORE, Liverpool, BC, England
[2] Univ New South Wales, Sydney, NSW, Australia
关键词
D O I
10.1200/JOP.2010.000019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Multidisciplinary meetings (MDMs) are increasingly being mandated as essential to oncology practice. However, there is a paucity of data on their effectiveness. The aim of this study was to assess whether MDM recommendations were concordant with guidelines in the treatment of lung cancer. Patients and Methods: The Lung Cancer Multidisciplinary Meeting in South West Sydney, Australia, prospectively collects data on all patients whose cases have been presented. New patients with lung cancer who presented between December 1, 2005, and December 31, 2007, were reviewed. Patients were assigned to treatment on the basis of evidencebased guidelines according to pathology, stage, and Eastern Cooperative Oncology Group (ECOG) performance status. MDM recommendations were compared with guideline treatment, and reasons for discrepancy were noted. Results: There were 335 patients with a median age of 69 years. Of these, 82% had non-small-cell lung cancer (NSCLC), 14% had small-cell lung cancer, and4% had no pathologic diagnosis. Eightyfour percent had locally advanced or metastatic disease. Concordance of MDM recommendations with guideline treatment existed in 29 (58%) of 50 cases for surgery, 201 (88%) of 228 cases for radiotherapy, and 200 (77%) of 260 cases for chemotherapy. Overall concordance with guideline treatment was 71% (239 of 335 cases). On multivariate analysis, age greater than 70 years, ECOG performance status of 2 or higher, and stage III NSCLC were associated with the MDM not recommending guideline treatment. The primary reasons for this were physician decision (39%), comorbidity (25%), and technical factors (22%). Conclusion: MDM recommendations were largely concordant with guidelines. Physician discretion in not recommending guideline treatment was most often exercised in older patients and those with borderline performance status. Individual factors that may preclude guideline treatment cannot be accounted for by guidelines.
引用
收藏
页码:276 / +
页数:8
相关论文
共 33 条
[11]  
2-9
[12]   The curative treatment by radiation therapy alone of Stage I non-small cell lung cancer in a geriatric population [J].
Gauden, SJ ;
Tripcony, L .
LUNG CANCER, 2001, 32 (01) :71-79
[13]   Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status [J].
Goss, Glenwood ;
Ferry, David ;
Wierzbicki, Rafal ;
Laurie, Scott A. ;
Thompson, Joyce ;
Biesma, Bonne ;
Hirsch, Fred R. ;
Varella-Garcia, Marileila ;
Duffield, Emma ;
Ataman, Ozlem U. ;
Zarenda, Marc ;
Armour, Alison A. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) :2253-2260
[14]   Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy [J].
Helbekkmo, Nina ;
Aasebo, Ulf ;
Sundstrom, Stein H. ;
von Plessen, Christian ;
Brunsvig, Paal Fr. ;
Bremnes, Roy M. .
LUNG CANCER, 2008, 62 (02) :253-260
[15]   Clinical benefit from palliative chemotherapy in non-small cell lung cancer extends to the elderly and those with poor prognostic factors [J].
Hickish, TF ;
Smith, IE ;
O'Brien, MER ;
Ashley, S ;
Middleton, G .
BRITISH JOURNAL OF CANCER, 1998, 78 (01) :28-33
[16]   Estimation of an optimal chemotherapy utilisation rate for lung cancer: An evidence-based benchmark for cancer care [J].
Jacob, Susannah ;
Hovey, Elizabeth ;
Ng, Weng ;
Vinod, Shalini ;
Delaney, Geoff P. ;
Barton, Michael B. .
LUNG CANCER, 2010, 69 (03) :307-314
[17]   Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in eastern cooperative oncology group performance status 2 non-small-cell lung cancer patients: ECOG 1599 [J].
Langer, Corey ;
Li, Sigui ;
Schiller, Joan ;
Tester, William ;
Rapoport, Bernardo L. ;
Johnson, David H. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (04) :418-423
[18]   Multidisciplinary management of lung cancer: How to test its efficacy? [J].
Leo, Francesco ;
Venissac, Nicolas ;
Poudenx, Michel ;
Otto, Josiane ;
Mouroux, Jerome .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (01) :69-72
[19]   Early mortality after radical radiotherapy for non-small-cell lung cancer: Comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center [J].
Mac Manus, MP ;
Wong, K ;
Hicks, RJ ;
Matthews, JP ;
Wirth, A ;
Ball, DL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (02) :351-361
[20]   Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational study [J].
Mahmud, SM ;
Reilly, M ;
Comber, H .
LUNG CANCER, 2003, 41 (01) :57-64